Company intelligence / Profile preview

Neuro3d

Mulhouse, Grand Est, France3dneuro.com ↗

Ownership: Private
Development stage: Other

Overview

Neuro3d developed small molecule drugs for central nervous system disorders. Its lead compound ocaperidone was nearing the end of Phase II trials for schizophrenia at the time of acquisition. Another candidate, ND1251 (a PDE4 inhibitor), entered clinical trials for depression with promising safety and efficacy profiles. The company’s strategy was to advance candidates through proof-of-concept before outlicensing or partnering them.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Janssen Pharmaceutica NV / Johnson & Johnson – licensing agreement on ocaperidone with option to license back after proof-of-concept studies completed by Neuro3d

Beyond the preview

Go deeper on Neuro3d.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuro3d.

Explore the full profile